Xilio Development Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.5
- Today's High:
- $2.63
- Open Price:
- $2.57
- 52W Low:
- $1.95
- 52W High:
- $4.92
- Prev. Close:
- $2.5
- Volume:
- 28860
Company Statistics
- Market Cap.:
- $79.86 million
- Book Value:
- 2.448
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-56774000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -40.21%
- Return on Equity TTM:
- -79.64%
Company Profile
Xilio Development Inc had its IPO on 2021-10-22 under the ticker symbol XLO.
The company operates in the Healthcare sector and Biotechnology industry. Xilio Development Inc has a staff strength of 84 employees.
Stock update
Shares of Xilio Development Inc opened at $2.57 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.5 - $2.63, and closed at $2.5.
This is a 0% increase from the previous day's closing price.
A total volume of 28,860 shares were traded at the close of the day’s session.
In the last one week, shares of Xilio Development Inc have slipped by -13.79%.
Xilio Development Inc's Key Ratios
Xilio Development Inc has a market cap of $79.86 million, indicating a price to book ratio of 0.5177 and a price to sales ratio of 0.
In the last 12-months Xilio Development Inc’s revenue was $0 with a gross profit of $-56774000 and an EBITDA of $-85062000. The EBITDA ratio measures Xilio Development Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Xilio Development Inc’s operating margin was 0% while its return on assets stood at -40.21% with a return of equity of -79.64%.
In Q2, Xilio Development Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Xilio Development Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-3.09 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Xilio Development Inc’s profitability.
Xilio Development Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.6405. Its price to sales ratio in the trailing 12-months stood at 0.
Xilio Development Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $92.36 million
- Total Liabilities
- $16.29 million
- Operating Cash Flow
- $-316000.00
- Capital Expenditure
- $316000
- Dividend Payout Ratio
- 0%
Xilio Development Inc ended 2024 with $92.36 million in total assets and $0 in total liabilities. Its intangible assets were valued at $92.36 million while shareholder equity stood at $67.38 million.
Xilio Development Inc ended 2024 with $0 in deferred long-term liabilities, $16.29 million in other current liabilities, 3000.00 in common stock, $-291109000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $75.38 million and cash and short-term investments were $75.38 million. The company’s total short-term debt was $8,126,000 while long-term debt stood at $0.
Xilio Development Inc’s total current assets stands at $78.43 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $197000.00 compared to accounts payable of $945000.00 and inventory worth $0.
In 2024, Xilio Development Inc's operating cash flow was $-316000.00 while its capital expenditure stood at $316000.
Comparatively, Xilio Development Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.5
- 52-Week High
- $4.92
- 52-Week Low
- $1.95
- Analyst Target Price
- $9.75
Xilio Development Inc stock is currently trading at $2.5 per share. It touched a 52-week high of $4.92 and a 52-week low of $4.92. Analysts tracking the stock have a 12-month average target price of $9.75.
Its 50-day moving average was $2.76 and 200-day moving average was $2.91 The short ratio stood at 8.68 indicating a short percent outstanding of 0%.
Around 1280.1% of the company’s stock are held by insiders while 6691.7% are held by institutions.
Frequently Asked Questions About Xilio Development Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.